Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis.

IF 5.6 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-22 DOI:10.1080/14760584.2026.2704173

Matthew Napier, Simon Brassel, Ellie Tunnicliffe, Claud Theakston, Stéphane Fievez, Yasmine Fahfouhi, Ayoub Boukhlal, Elisabeth Botelho-Nevers, Olivier Guerin, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten

{"title":"Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis.","authors":"Matthew Napier, Simon Brassel, Ellie Tunnicliffe, Claud Theakston, Stéphane Fievez, Yasmine Fahfouhi, Ayoub Boukhlal, Elisabeth Botelho-Nevers, Olivier Guerin, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten","doi":"10.1080/14760584.2026.2704173","DOIUrl":null,"url":null,"abstract":"Background: Pneumococcal disease, respiratory syncytial virus (RSV), influenza, and COVID-19 place a significant burden on France's population health, health system, and economy. Older adults and adults in clinical risk groups are recommended to receive vaccination against these illnesses, although RSV is not reimbursed.Research design and methods: A benefit-cost analysis was conducted to assess the societal return on investment from adult vaccination by estimating benefit-cost ratios (BCRs) and net benefits (NBs). Health outcomes were monetized using established methods. Program costs included all direct vaccination-related expenditures. Scenario and sensitivity analyses assessed alternative program specifications and tested the robustness of the model.Results: France's age-based respiratory immunization programs generate a BCR of €2.0 to €8.7 per €1 spent over the lifetime, depending on mortality risk reduction monetization. This corresponds to NBs of €9.7 to €72.6 billion. Introducing adult RSV vaccination with a similar uptake to that in the US could increase NBs by approximately 6%-7% compared to the status quo. Achieving aspirational coverage targets across all programs would increase NBs by 138%-175%.Conclusions: France's adult respiratory vaccination programs generate positive socioeconomic returns. Including adult RSV vaccination and increasing vaccination uptake would further increase their societal benefits. Realizing these gains requires adequate public investment.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2704173"},"PeriodicalIF":5.6000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2026.2704173","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pneumococcal disease, respiratory syncytial virus (RSV), influenza, and COVID-19 place a significant burden on France's population health, health system, and economy. Older adults and adults in clinical risk groups are recommended to receive vaccination against these illnesses, although RSV is not reimbursed.

Research design and methods: A benefit-cost analysis was conducted to assess the societal return on investment from adult vaccination by estimating benefit-cost ratios (BCRs) and net benefits (NBs). Health outcomes were monetized using established methods. Program costs included all direct vaccination-related expenditures. Scenario and sensitivity analyses assessed alternative program specifications and tested the robustness of the model.

Results: France's age-based respiratory immunization programs generate a BCR of €2.0 to €8.7 per €1 spent over the lifetime, depending on mortality risk reduction monetization. This corresponds to NBs of €9.7 to €72.6 billion. Introducing adult RSV vaccination with a similar uptake to that in the US could increase NBs by approximately 6%-7% compared to the status quo. Achieving aspirational coverage targets across all programs would increase NBs by 138%-175%.

Conclusions: France's adult respiratory vaccination programs generate positive socioeconomic returns. Including adult RSV vaccination and increasing vaccination uptake would further increase their societal benefits. Realizing these gains requires adequate public investment.

查看原文本刊更多论文

量化法国成人呼吸道疾病免疫接种的社会效益：效益成本分析。

背景：肺炎球菌病、呼吸道合胞病毒（RSV）、流感和COVID-19给法国的人口健康、卫生系统和经济带来了重大负担。建议老年人和临床危险人群中的成年人接种针对这些疾病的疫苗，尽管呼吸道合胞病毒不报销。研究设计和方法：通过估算效益成本比（bcr）和净效益（NBs），进行了效益成本分析，以评估成人疫苗接种投资的社会回报。使用既定方法将健康结果货币化。规划费用包括所有与疫苗接种直接相关的支出。情景分析和敏感性分析评估了备选方案规范，并测试了模型的稳健性。结果：法国基于年龄的呼吸道免疫计划产生的BCR为每1欧元在一生中花费2.0至8.7欧元，这取决于死亡率风险降低货币化。这相当于97亿至726亿欧元的国债。引入与美国相似的成人呼吸道合胞病毒疫苗接种，与现状相比可使NBs增加约6%-7%。实现所有项目的理想覆盖目标将使国民收入增加138%-175%。结论：法国的成人呼吸道疫苗接种计划产生了积极的社会经济回报。包括成人呼吸道合胞病毒疫苗接种和增加疫苗接种率将进一步增加其社会效益。实现这些成果需要充分的公共投资。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.